SUSTAINED THERAPEUTICS - Key Persons
Job Titles:
- Founder and Retired Chief Executive Officer and Chairman of Endo Pharmaceuticals Inc
- President of the Generic Pharmaceutical Business Unit of the DuPont Merck Pharmaceutical Company
- Retired CEO and Chair
Carol A. Ammon is the founder and retired chief executive officer and chairman of Endo Pharmaceuticals Inc., a specialty pharmaceutical company based in Chadds Ford, Penn. In May 2005, Ms. Ammon retired as CEO after serving in that position since 1997.
Before she founded Endo Pharmaceuticals, Ms. Ammon spent 23 years in the pharmaceutical division of E.I. du Pont de Nemours and Company where she served in positions of increasing responsibility across research and development, finance, manufacturing, and sales and marketing.
Job Titles:
- Solicitor, Parolin Consulting Law Corporation
Mr. Parolin is a commercial lawyer. He was a founding partner of McClellan, Rubenstein & Parolin, which was formed in 1994, and continued that firm's practice by way of its successor firm, Parolin & Company, until 2013. He is currently providing legal and advisory services through his law corporation, Parolin Consulting Law Corporation. Mr. Parolin obtained a Bachelor of Arts degree in 1984, and a Bachelor of Laws degree in 1987, from Queen's University.
Job Titles:
- Professor, Clinician Scientist, Kingston ( KGHRI )
Job Titles:
- Chief Operating Officer
- Founder
- Member of the Leadership Team
Dr. Boniface has spent more than 20 years in drug development in both the private and public sectors. Since 2008, he has been the COO of the Vancouver Prostate Centre, a world-renown cancer research and treatment facility. Prior to this he was the Senior Director of Clinical Research at QLT Inc. where he oversaw the development of multiple drug platforms that received FDA, Health Canada, and European agency approvals.
Job Titles:
- Professor, Division of Urology, University of Toronto
Job Titles:
- Obstetrician - Gynecologist
Job Titles:
- Chief Medical Officer
- Founder
- Member of the Leadership Team
- Distinguished Professor and Chair of the Department of Urologic Sciences
Dr. Gleave is a Distinguished Professor and Chair of the Department of Urologic Sciences at the University of British Columbia. A clinician-scientist and urologic surgeon who has published more than 600 research papers, Dr. Gleave has raised over $120M in funding and co-founded biopharma startup OncoGenex, which was successfully acquired in 2017. In 2018, he was appointed to the Order of Canada for his research into cancer treatment resistance and developing new treatments for prostate cancer.
Job Titles:
- Professor, Department of Anesthesia and Perioperative Care, University of California
Job Titles:
- Member of the Leadership Team
- Research Scientist
- Director, Product Development
Dr. Schmitt is an accomplished research scientist who received her PhD in Drug Delivery and Nanomedicine from the University of British Columbia in 2015. A registered German pharmacist, she has published 13 papers in subjects ranging from pharmacokinetics to mechanical and physiological skin properties to general pharmacology. At Sustained Therapeutics, she works on formulation design, preclinical testing, clinical research, and manufacturing.
Howard has over twenty-five years of Canadian and U.S. corporate pharmaceutical senior commercial management experience. Howard has also gained pharmaceutical experience as a founder and CEO of Verity Pharmaceuticals and co-founder of POINT Global BioPharma Global Inc.. Moreover, Howard was a founder and CEO of a medical market research company (MD Analytics Inc), and a scientific communications and medical education business which launch Medscape/WebMD in Canada.
Job Titles:
- Chief Executive Officer
- Leader
- Member of the Leadership Team
Mr. Annett is a highly experienced leader with a successful track record in the life sciences industry. He has been CEO of four early stage companies, taking two of them public and exiting a third via acquisition. He was also a Partner at Accenture, where he led the West Coast Life Sciences practice. In addition he spent eight years at Genentech where he led the Launch Office, directed the Project Finance function supporting all Development pipeline products, and led numerous large operational transformation projects. Mr. Annett received his MBA from the Harvard Business School.